Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects.
Rusconi S, Saladini F, Bellocchi MC, Galli L, Gagliardini R, Gazzola L, Francisci D, Vichi F, Focà E, Zazzi M, Santoro MM, Gabrieli A, Castagna A; PRESTIGIO Registry study group; PRESTIGIO Registry Steering Committee: Antonella Castagna (coordinator); Stefano Bonora; Leonardo Calza; Antonella Castagna; Giovanni Cenderello; Adriana Cervo; Giulio Maria Corbelli; Antonio Di Biagio; Emanuele Focà; Roberta Gagliardini; Laura Galli; Riccardo Lolatto; Franco Maggiolo; Giulia Marchetti; Stefano Rusconi; Maria Santoro; Vincenzo Spagnuolo; Katia Sterrantino; Maurizio Zazzi. Rusconi S, et al. Among authors: zazzi m. Pharmacol Res. 2022 Feb;176:106064. doi: 10.1016/j.phrs.2022.106064. Epub 2022 Jan 6. Pharmacol Res. 2022. PMID: 34999223 No abstract available.
Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.
De Luca A, Di Giambenedetto S, Romano L, Gonnelli A, Corsi P, Baldari M, Di Pietro M, Menzo S, Francisci D, Almi P, Zazzi M; Antiretroviral Resistance Cohort Analysis Study Group. De Luca A, et al. Among authors: zazzi m. J Infect Dis. 2006 May 1;193(9):1219-22. doi: 10.1086/502976. Epub 2006 Mar 28. J Infect Dis. 2006. PMID: 16586357
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy.
Saladini F, Vicenti I, Razzolini F, Zazzi M. Saladini F, et al. Among authors: zazzi m. Clin Microbiol Infect. 2010 Jul;16(7):848-51. doi: 10.1111/j.1469-0691.2009.03005.x. Epub 2009 Jul 21. Clin Microbiol Infect. 2010. PMID: 19681953 Free article.
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.
Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A; ARCA database initiative. Gianotti N, et al. Among authors: zazzi m. J Med Virol. 2011 Mar;83(3):391-8. doi: 10.1002/jmv.21989. J Med Virol. 2011. PMID: 21264858
314 results